Back to Report Store Home

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • Published: Sep-2017
  • Report Code: GBIHC455MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Diabetes Drugs Market, Global, Epidemiology Patterns for T1DM, 2016–2023

Figure 2: Diabetes Drugs Market, Global, Epidemiology Patterns for T2DM, 2016–2023

Figure 3: Diabetes Drugs Market, Global, Market Share Projections for Key Established Products, 2016–2023

Figure 4: Diabetes Drugs Market, Global, Market Share Projections for Key Upcoming Products, 2016–2023

Figure 5: Diabetes Drugs Market, Global, Percentage Change in Market Share for Key Products 2016–2023

Figure 6: Diabetes Drugs Market, Global, Key Marketed Products and Approved Indications, 2017

Figure 7: Diabetes Drugs Market, Global, Annual Revenue for Lantus ($bn), 2006–2023

Figure 8: Diabetes Drugs Market, Global, Annual Revenue for Levemir ($bn), 2006–2023

Figure 9: Diabetes Drugs Market, Global, Annual Revenue for Tresiba ($bn), 2016–2023

Figure 10: Diabetes Drugs Market, Global, Annual Revenue for Toujeo ($bn), 2015–2023

Figure 11: Diabetes Drugs Market, Global, Annual Revenue for Humalog ($bn), 2006–2023

Figure 12: Diabetes Drugs Market, Global, Annual Revenue for Novolog ($bn), 2006–2023

Figure 13: Diabetes Drugs Market, Global, Annual Revenues for Apidra ($m), 2009–2023

Figure 14: Diabetes Drugs Market, Global, Annual Revenues for Victoza ($bn), 2009–2023

Figure 15: Diabetes Drugs Market, Global, Annual Revenue for Trulicity ($bn), 2014–2023

Figure 16: Diabetes Drugs Market, Global, Annual Revenue for Januvia ($bn), 2006–2023

Figure 17: Diabetes Drugs Market, Global, Annual Revenue for Galvus ($bn), 2007–2023

Figure 18: Diabetes Drugs Market, Global, Annual Revenues for Tradjenta ($m), 2011–2023

Figure 19: Diabetes Drugs Market, Global, Annual Revenues for Invokana ($bn), 2013–2023

Figure 20: Diabetes Drugs Market, Global, Annual Revenue for Jardiance ($bn), 2014–2023

Figure 21: Diabetes Drugs Market, Global, Annual Revenue for Farxiga ($bn), 2013–2023

Figure 22: Diabetes Drugs Market, Global, Annual Revenues for Soliqua 100/33 ($m), 2017–2023

Figure 23: Diabetes Drugs Market, Global, Annual Revenue for Xultophy ($bn), 2017–2023

Figure 24: Diabetes Drugs Market, Global, Annual Revenue for Janumet ($bn), 2007–2023

Figure 25: Diabetes Drugs Market, Global, Annual Revenue for Qtern ($m), 2017–2023

Figure 26: Diabetes Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017

Figure 27: Diabetes Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017

Figure 28: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Stage of Development, 2017

Figure 29: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecule Type, 2017

Figure 30: Diabetes Drugs Market, Global, Pipeline by Molecular Target, 2017

Figure 31: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecular Target, 2017

Figure 32: Diabetes Drugs Market, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006–2017

Figure 33: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Indication (%), 2006–2017

Figure 34: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecule Type (%), 2006–2017

Figure 35: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecular Target (%), 2006–2017

Figure 36: Diabetes Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2017

Figure 37: Diabetes Drugs Market, Global, Clinical Trial Duration by Indication and Stage of Development (months), 2006–2017

Figure 38: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006–2017

Figure 39: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006–2017

Figure 40: Diabetes Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006–2017

Figure 41: Diabetes Drugs Market, Global, Clinical Trial Size by Indication and Stage of Development (participants), 2006–2017

Figure 42: Diabetes Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006–2017

Figure 43: Diabetes Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (Participants), 2006–2017

Figure 44: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development, 2006–2017

Figure 45: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Indication and Stage of Development (participants), 2006–2017

Figure 46: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecule Type and Stage of Development (participants), 2006–2017

Figure 47: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecular Target and Stage of Development (participants), 2006–2017

Figure 48: Diabetes Drugs Market, Global, Revenue Forecast for Semaglutide (NN-9535) ($bn), 2017–2023

Figure 49: Diabetes Drugs Market, Global, Revenue Forecast for Oral Semaglutide (OG-217SC) ($bn), 2020–2023

Figure 50: Diabetes Drugs Market, Global, Revenue Forecast for ITCA 650 ($bn), 2018–2023

Figure 51: Diabetes Drugs Market, Global, Revenue Forecast for Sotagliflozin ($bn), 2018–2023

Figure 52: Diabetes Drugs Market, Global, Revenue Forecast for Ertugliflozin ($m), 2017–2023

Figure 53: Diabetes Drugs Market, Global, Annual Revenue Forecast, 2016–2023

Figure 54: Diabetes Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016–2023

Figure 55: Diabetes Drugs Market, Global, Annual Revenue Forecast for Insulin Receptors ($bn), 2016–2023

Figure 56: Diabetes Drugs Market, Global, Annual Revenue Forecast for GLP-1 Receptors, 2016–2023

Figure 57: Diabetes Drugs Market, Global, Annual Revenue Forecast for SGLT-2 Inhibitors, 2016–2023

Figure 58: Diabetes Drugs Market, Global, Annual Revenue Forecast for DPP-4 Inhibitors, 2016–2023

Figure 59: Diabetes Drugs Market, Global, Cluster by Growth and Market Share, 2016–2023

Figure 60: Diabetes Drugs Market, Global, Forecast Market Share by Company (%), 2016–2023

Figure 61: Diabetes Drugs Market Global, Companies by Compound Annual Growth Rate (%), 2016–2023

Figure 62: Diabetes Drugs Market, Global, Revenue by Route of Acquisition, 2016–2023

Figure 63: Diabetes Drugs Market, Global, Novo Nordisk Annual Revenue Forecast, ($bn), 2016–2023

Figure 64: Diabetes Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2016–2023

Figure 65: Diabetes Drugs Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016–2023

Figure 66: Diabetes Drugs Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016–2023

Figure 67: Diabetes Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2016–2023

Figure 68: Diabetes Drugs Market, Global, Merck and Co Annual Revenue Forecast ($bn), 2016–2023

Figure 69: Diabetes Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2016–2023

Figure 70: Diabetes Drugs Market, Global, Pipeline Developers by Level of Diabetes Specialization, 2016–2023

Figure 71: Diabetes Drugs Market, Global, Proportion of Total Company Revenue Attributable to Diabetes, 2016–2023

Figure 72: Diabetes Drugs Market, Licensing Deals by Region, Value and Year, 2006–2017

Figure 73: Diabetes Drugs Market, Global, Number of Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017

Figure 74: Diabetes Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2017

Figure 75: Diabetes Drugs Market, Global, Licensing Deals Valued at $100m and above, 2006–2017

Figure 76: Diabetes Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006–2017

Figure 77: Diabetes Drugs Market, Global, Number of Co-development Deals by Value and Stage of Development, 2006–2017

Figure 78: Diabetes Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2017

Figure 79: Diabetes Drugs Market, Global, Co-development Deals Valued at $100m and above, 2006–2017

Figure 80: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 1)

Figure 81: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 2)

Figure 82: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 3)

Figure 83: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 4)

Figure 84: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 5)

Figure 85: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 6)

Figure 86: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 7)

Figure 87: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 8)

Figure 88: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 9)

Figure 89: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 10)

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards